Furthermore, CD30 expression is increased in bone marrow samples of T-ALL patients treated with high-dose chemotherapy, indicating that application of anti-CD30 immunotherapy should be considered when designing new trials for CD30+ r/r T-ALL patients. Here, TNFRSF8 is linked to acute lymphoblastic leukemia.